文献速递鼻科

dupilumab与内镜鼻窦手术治疗慢性鼻窦炎伴鼻息肉的成本效用分析

Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
PubMed 文献 · Laryngoscope · 2020-04-03

该研究采用队列式马尔可夫决策树经济模型,比较dupilumab与内镜鼻窦手术(ESS)治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的成本效益。基于197例ESS患者与293例dupilumab治疗患者的匹配队列,结果显示ESS策略成本50,436.99美元并产生9.80 QALYs,dupilumab策略成本536,420.22美元并产生8.95 QALYs,dupilumab被ESS支配。结论认为ESS upfront治疗更具成本效益。

要点

  • ESS策略成本50,436.99美元,产生9.80 QALYs。
  • dupilumab策略成本536,420.22美元,产生8.95 QALYs。
  • dupilumab因成本更高且效果更差被ESS支配。

核心结论

  • 对于CRSwNP的upfront治疗,ESS策略比dupilumab更具成本效益。

研究设计与样本

  • 队列式马尔可夫决策树经济模型,时间跨度36年。
  • 比较197例接受ESS的CRSwNP患者与293例来自SINUS-24和SINUS-52三期研究的匹配CRSwNP患者(接受dupilumab 300 mg每2周治疗)。
  • 效用评分通过SNOT-22工具计算,决策树分析和10状态马尔可夫模型使用已发表的事件概率和原始数据计算长期成本和效用。

主要发现

  • ESS策略成本50,436.99美元,产生9.80 QALYs。
  • dupilumab策略成本536,420.22美元,产生8.95 QALYs。
  • 在基础案例中,dupilumab被ESS支配(成本更高且效果更差)。
  • 单因素敏感性分析显示,无论修正手术频率如何,以及dupilumab年成本高于855美元的任何情况下,ESS相对于dupilumab均具有成本效益。

关键数值与推荐

  • 主要结局指标为每质量调整生命年增量成本(QALY),表示为增量成本效果比。
  • dupilumab剂量为300 mg每2周一次。

临床怎么用

  • 对于CRSwNP的upfront治疗,ESS应优先考虑作为更具成本效益的策略。
  • 需要更多研究来识别哪些表型或内型患者能从dupilumab治疗中以成本效益方式最大获益。

局限性

  • 需要更多研究来分离出将以成本效益方式最大受益于dupilumab的潜在表型或内型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Both endoscopic sinus surgery (ESS) and biologic therapies have shown effectiveness for medically-refractory chronic rhinosinusitis with nasal polyps (CRSwNP) without severe asthma. The objective was to evaluate cost-effectiveness of dupilumab versus ESS for patients with CRSwNP. STUDY DESIGN: Cohort-style Markov decision-tree economic model with a 36-year time horizon. METHODS: A cohort of 197 CRSwNP patients who underwent ESS were compared with a matched cohort of 293 CRSwNP patients from the SINUS-24 and SINUS-52 Phase 3 studies who underwent treatment with dupilumab 300 mg every 2 weeks. Utility scores were calculated from the SNOT-22 instrument in both cohorts. Decision-tree analysis and a 10-state Markov model utilized published event probabilities and primary data to calculate long-term costs and utility. The primary outcome measure was incremental cost per quality-adjusted life year (QALY), which is expressed as an Incremental Cost Effectiveness Ratio. One-way and probabilistic sensitivity analyses were performed. RESULTS: The ESS strategy cost $50,436.99 and produced 9.80 QALYs. The dupilumab treatment strategy cost $536,420.22 and produced 8.95 QALYs. Because dupilumab treatment was more costly and less effective than the ESS strategy, it is dominated by ESS in the base case. One-way sensitivity analyses showed ESS to be cost-effective versus dupilumab regardless of the frequency of revision surgery and at any yearly cost of dupilumab above $855. CONCLUSIONS: The ESS treatment strategy is more cost effective than dupilumab for upfront treatment of CRSwNP. More studies are needed to isolate potential phenotypes or endotypes that will benefit most from dupilumab in a cost-effective manner. LEVEL OF EVIDENCE: 2C Laryngoscope, 131:E26-E33, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Scangas GA, Wu AW, Ting JY, et al. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope. 2020. PMID: 32243622. doi:10.1002/lary.28648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。